Voluntis and Bristol-Myers Squibb to co-develop digital therapeutics for oncology

Bristol-Myers SquibbVoluntis (Euronext Paris, Ticker: VTX - ISIN: FR0004183960), a leader in digital therapeutics, and Bristol-Myers Squibb Company (NYSE:BMY) announced a collaboration agreement to create and investigate digital therapeutic solutions that will support cancer patients. Leveraging Theraxium Oncology, Voluntis' core platform for digital therapeutics in oncology, the collaboration will evaluate potential solutions that will support management of patient symptoms and remote monitoring by healthcare providers.

The goal is that the digital therapeutic, once researched and developed, would provide patients access to a mobile app that would support treatment and track symptoms. The app will be developed to embed evidence-based algorithms intended to provide patients with real-time recommendations for self-management of symptoms related to their therapy. The parties will also investigate how the solution could enable patients to more effectively communicate with their health care providers, capture and track symptoms, and receive a personalized supportive care plan.

Paul von Autenried, Chief Information Officer, Bristol-Myers Squibb, said, "This collaboration with Voluntis is an example of our commitment to advance patient care with digital solutions. By developing new technology and patient-centered initiatives such as these, we hope to advance the standards of clinical practice."

Pierre Leurent, CEO of Voluntis: "Bristol-Myers Squibb is a leading innovator in oncology. We are delighted to join forces with their talented teams to work on digital therapeutics that could have a significant impact on the treatment experience for patients worldwide. This collaboration is a recognition of our unique know-how and technology, as well as an important opportunity to bring it to scale in oncology."

About Bristol-Myers Squibb

Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases.

Most Popular Now

Pfizer receives positive FDA Advisory Committee vo…

Pfizer Inc. (NYSE: PFE) announced that the U.S. Food and Drug Administration's (FDA) Vaccines and Related Biological Products Advisory Committee (VRBPAC) voted that avail...

Engineered bacteria find tumors, then alert the au…

Combining discoveries in cancer immunology with sophisticated genetic engineering, Columbia University researchers have created a sort of "bacterial suicide squad" that ...

First nasal monoclonal antibody treatment for COVI…

A pilot trial by investigators from Brigham and Women's Hospital, a founding member of the Mass General Brigham healthcare system, tested the nasal administration of the ...

US FDA Advisory Committee votes to support effecti…

GSK plc (LSE/NYSE: GSK) announced that the US Food and Drug Administration (FDA) Vaccines and Related Biological Products Advisory Committee (VRBPAC) voted that the avail...

"Semantic similarity" leads to novel dru…

The words that researchers use to describe their results can be harnessed to discover potential new treatments for Parkinson's disease, according to a new study published...

Tumour cells' response to chemotherapy is driven b…

Cancer cells have an innate randomness in their ability to respond to chemotherapy, which is another tool in their arsenal of resisting treatment, new research led by the...

Pfizer's ZAVZPRET™ (zavegepant) migraine nasal spr…

Pfizer Inc. (NYSE: PFE) today announced the U.S. Food and Drug Administration (FDA) has approved ZAVZPRET™ (zavegepant), the first and only calcitonin gene-related peptid...

Pfizer invests $43 billion to battle cancer

Pfizer Inc. (NYSE: PFE) and Seagen Inc. (Nasdaq: SGEN) today announced that they have entered into a definitive merger agreement under which Pfizer will acquire Seagen, a...

Gene and cell therapies to combat pancreatic cance…

Pancreatic cancer is an incurable form of cancer, and gene therapies are currently in clinical testing to treat this deadly disease. A comprehensive review of the gene an...

Scientists reveal a potential new approach to trea…

Scientists at the National Institutes of Health and Massachusetts General Hospital in Boston have uncovered a potential new approach against liver cancer that could lead ...

Normalizing tumor blood vessels may improve immuno…

A type of immune therapy called chimeric antigen receptor (CAR)-T cell therapy has revolutionized the treatment of multiple types of blood cancers but has shown limited e...

Digital twin opens way to effective treatment of i…

Inflammatory diseases like rheumatoid arthritis have complex disease mechanisms that can differ from patient to patient with the same diagnosis. This means that currently...